Print

Programme 2013

 

 
 
  The Critical Issues 2013 faculty was composed of more than
60 outstanding faculty members from more than 10 countries
around the world. More than 60 lectures were presented during
Critical Issues 2013.

To review any of the authorized presentations, please click this link:
Critical Issues 2013 presentations
   
   
   
   
Friday, June 21
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 
07:45 – 08:15 Registration and Coffee
   
08:15 – 08:30 Introduction E. Verhoeven
   
8:30 – 10:30 Session 1: The practical session – part I
Chairmen: E. Verhoeven, M. Thompson
Commentator: J. Fernandes e Fernandes
08:30 – 08:36 AAA is progressive disease: implications for patient and technique selection J. Brennan
08:37 – 08:43 Angulated necks: implications with regard to oversizing and when not to treat by EVAR? F. Moll
08:44 – 08:50 Addressing the severely angulated neck with EVAR J. Hardman
08:51 – 08:57 Low profile grafts will expand indications or result in EVAR treatment of non-suitable patients? D. Adam
08:58 – 09:04 Low profile grafts: are there patients that we should not treat even if we can get the grafts in? M. Tenholt
09:04 – 09:30
Discussion
09:30 – 09:36 The evidence for pre-operative embolization of aortic branches prior to EVAR R. Mc Williams
09:37 – 09:43 Interpretation of the CAESARS trial: when should we (if at all) treat small AAA? P. Cao
09:44 – 09:50 Which neck length is required in the arch and which devices can accommodate the arch? D. Böckler
09:51 – 09:57 Long-term results of iliac branched endografts: the role of different hypogastric stent-grafts? F. Verzini
09:58 – 10:04 Treatment of traumatic thoracic injury, lessons learned from the past and a look into the future M. Lachat
10:04 – 10:30
Discussion
   
10:30 – 11:00 Break
   
11:00 – 12:15 Session 2: The modesty session – EVAR update and new concepts
Chairmen: M. Malina, W. Ritter
Commentator: D. Raithel
11:00 – 11:06 How valid are randomized EVAR trials in the face of current and new device technology? J. Blankensteijn
11:07 – 11:13 New EVAR techniques or devices: what do we need to demonstrate efficacy and durability? M. Thompson
11:14 – 11:20 Lessons learned from the ENGAGE registry: how far can we go with standard EVAR? H. Verhagen
11:21 – 11:27 Lessons learned from the GREAT registry on C3 Excluder E. Verhoeven
11:27 – 11:35
Discussion
11:35 – 11:41 The Cordis INCRAFT AAA Endograft: Next generation technology that combines low profile with ease of use B. Gehringhoff
11:42 – 11:48 Sealing is believing. How an innovative sealing (TRIVASCULAR) changes the approach to EVAR? M. Tenholt
11:49 – 11:55 The benefits of treating complex AAA anatomy on label with Aorfix? N. Mosquera
11:56 – 12:02 NELLIX provides an interesting new concept. What is next? A. Holden
12:03 – 12:08 Aptus endoanchors: as a rescue or to expand indications of standard EVAR? J-P. de Vries
12:08 – 12:15
Discussion
   
12:15 – 13:15 Session 3: The selection session in pararenal AAA
Chairmen: J. Brennan, J. Blankensteijn
Commentator: J. Busquet
12:15 – 12:21 The literature evidence in short necked AAA: what to propose first? I. Loftus
12:22 – 12:28 Which solution for which patient: how to find the best solution for each individual patient? M. Austermann
12:29 – 12:35 Update on the fenestrated Anaconda J. Brunkwall
12:36 – 12:42 Open chimney for juxta renal AAA E. Ducasse
12:43 – 12:49 Pitfalls and technical tips for CHEVAR and SNEVAR A. Assadian
12:50 – 12:56 Technique to make home-fenestrated grafts J. Ricotta
12:57 – 13:03 New concept inner branch for visceral vessels: does it work? For which patients? M. Ferreira
13:03 – 13:15
Discussion
   
13:15 – 14:30
Lunch
   
14:30 – 16:15 Session 4: Top gun session – TAAA treatment
Chairmen: R. Mc Williams, F. Vermassen
Commentator: T. Mastracci
14:30 – 14:36 Results of endovascular repair of TAAA: how to select the right patients? Which patients should not be treated at all? R. Greenberg
14:37 – 14:43 Which TAAA patients should be treated with open techniques and which patients should not be treated at all? M. Jacobs
14:44 – 14:50 Are sandwich grafts in TAAA a real alternative to custom made branched devices? R. Kolvenbach
14:51 – 14:57 Chimneys and in-situ grafts in the arch M. Malina
14:57 – 15:22
Discussion
15:22 – 15:28 The arch branched device: results improve quickly on the short term but what to expect from the longer term and which alternative techniques are possible? K. Ivancev
15:29 – 15:35 Apical approach for TEVAR: a fine and safe solution in difficult cases or just another gimmick? T. Kölbel
15:36 – 15:42 Total arch repair with a novel branched graft. In which patients can we use this device? Q. Lu
15:43 – 15:49 Frozen elephant trunk with the Vascutek Thoraflex Prosthesis M. Pichlmaier
15:50 – 15:56 The Medtronic LSA branch Valiant thoracic device: which patients do we target? M. Thompson
15:56 – 16:15
Discussion
   
16:15 – 16:45
Break
   
16:45 – 18:15 Session 5: The decision session about Type B dissections
Chairmen: T. Resch, P. Taylor
Commentator: M. Ferreira
16:45 – 16:51 Comparison of endovascular and medical therapy in uncomplicated Type B dissection: lessons learned Q. Lu
16:52 – 16:58 The long term results of Instead underline that uncomplicated Type B dissections should be treated early with TEVAR. Are there patients that should NOT be treated? C. Nienaber
16:59 – 17:05 Arguments to treat uncomplicated acute Type B dissection M. Thompson
17:06 – 17:12 Adsorb was totally underpowered, but still shows that acute Type B dissection should be treated J. Brunkwall
17:13 – 17:18 Predictors of success following TEVAR for chronic dissection P. Taylor
17:19 – 17:25 Fenestrated grafts for chronic Type B dissections: the Cleveland Clinic approach R. Greenberg
17:25 – 18:15 Discussion
   
   
19:00 – 20:00 Reception
   
20:00 – 23:00 Congress dinner and get together
Old Town Hall Nuremberg (walking distance)
   
   
Saturday, June 22
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 
08:00 – 08:15 Welcome and coffee
   
08:15 – 10:00 Sesssion 6: The practical session – part II
Follow-up and complications session
Chairmen: S. Haulon, D. Raithel
Commentator: J. Fernandes e Fernandes
08:15 – 08:21 Renal outcome after FEVAR/BEVAR and CHEVAR: what can we really expect? G. Hamilton
08:22 – 08:28 Long term results with fenestrated grafts with covered stents for the fenestrations I. Tielliu
08:29 – 08:35 Improved results with the new Atrium V12? E. Verhoeven
08:36 – 08:42 EVAR follow-up: is it time to discuss individualized follow-up schemes based on preoperative anatomy and high quality completion angiography? G. Pratesi
08:43 – 08:49 Follow-up without CT: why and when? K. Oikonomou
08:50 – 08:56 Overview of endoleaks and diagnostic algorythm G. Maleux
08:57 – 09:03 How to treat endoleaks Type I and III A. Holden
09:04 – 09:10 When and how to treat endoleaks Type II R. Mc Williams
09:04 – 10:00
Discussion
   
10:00 – 10:30
Break
   
10:30 – 11:45 Session 7: The imaging session with the clash of the Titans
Chairmen: R. Mc Williams, T. Resch
Commentator: W. Ritter
10:30 – 10:36 Siemens flash presentation: new developments with Siemens G. Nollert
10:37 – 10:43 Working flow with the new Artis Zeego Hybrid room in New York N. Cayne
10:44 – 10:50 GE flash presentation: new developments with GE M. Grimaud
10:51 – 10:57 The GE hybrid room changed my (working) life S. Haulon
10:58 – 11:04 How to build a hybrid room that works at once? H. Eckstein
11:05 – 11:11 Dyna CT in the hybrid OR: how and when to use? M. Steinbauer
11:12 – 11:18 Future imaging techniques in aortic pathologies and clinical implications R. Clough
11:18 – 11:45
Discussion
   
11:45 – 13:00 Session 8: The acute session and the difficult road to off-the-shelf grafts
Chairmen: P. Taylor, W. Wisselink
Commentator: S. Haulon
11:45 – 11:51 The Ajax trial results: implications for the future W. Wisselink
11:52 – 11:58 Set-up for endovascular acute AAA treatment in Malmö: how to treat more than 90% of patients by endovascular means M. Malina
11:59 – 12:05 Acute pararenal AAA: the homemade surgeon-modified fenestrated graft, no future? J. Ricotta
12:05 – 12:20
Discussion
12:20 – 12:26 Off-the-shelf TAAA devices-is one device enough? P. Kasprzak
12:27 – 12:33 The Ventana off-the-shelf graft for pararenal AAA A. Holden
12:34 – 12:40 Results with the new Cook p-branch fenestrated device for pararenal AAA T. Resch
12:41 – 12:47 First-in-man with the new Medtronic branched device. Which patients to target, and how to avoid use in the wrong patients? F. Arko
12:47 – 13:00
Discussion
   
13:00 – 14:00
Lunch
   
14:00 – 15:30 Session 9: The blast from the past session: come on, give us a follow up
Chairmen: E. Verhoeven, R. Greenberg
Commentator: T. Resch
14:00 – 14:06 Late paraplegia after endovascular TAAA repair F. Vermassen
14:07 – 14:13 Staged TAAA repair? Does it really help, if yes why? T. Mastracci
14:14 – 14:20 Extra branch for spinal cord perfusion? Do the results prove us right? P. Kasprzak
14:21 – 14:27 Monitoring spinal cord function during TAAA branched grafting, mandatory? G.W.H. Schurink
14:28 – 14:34 Short neck in standard EVAR: does it really work? Long-term results? J. Teßarek
14:35 – 14:41 EVAR in short/no necked RAAA? Outcome? M. Malina
14:42 – 14:48 Distal fenestration for TAAA Type I: late extension of disease? V. Riambau
14:49 – 14:55 The renal side of the story: long term results R. Greenberg
14:56 – 15:02 Robotic surgery in vascular surgery, an update N. Cheshire
15:02 – 15:30
Discussion
   
15:30 Adjourn
   
   
16:00
Buses leave for Siemens Erlangen/Forchheim
   
16:30 – 18:30
Visit Siemens factory
   
19:00 – 23.00
Visit Vaults in Forchheim & Get together (Local beer & Food party)
   
  icon Download programme